S. Keller

H. Wakelee, D. Gandara, S. Ramalingam, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer

Thomas M. Harris, R. Perez-soler, J. Locker, 2010, Clinical Cancer Research.

Since chemotherapy is now the standard in node-positive lung cancer, what is the role of postoperative radiotherapy?

A. Turrisi, S. Keller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

J. Jett, M. Hammond, R. Livingston, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review Neoadjuvant and adjuvant therapy ofnon-small cell lung cancer

L. Rajdev, S. Keller, 2002 .

Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: An intergroup trial (E3590)

S. Adak, R. Livingston, M. Perry, 2000 .

DNA content in correlation with postsurgical stage in non-small cell lung cancer.

P. Watts, M. Chang, P. Watts, 1992, The Annals of thoracic surgery.

Report of phase II trial of concurrent chemoradiotherapy with radical thoracic irradiation (60 Gy), infusional fluorouracil, bolus cisplatin and etoposide for clinical stage IIIB and bulky IIIA non-small cell lung cancer.

W. Curran, S. Litwin, C. Langer, 1993, International journal of radiation oncology, biology, physics.

Chromosome alterations in 21 non‐small cell lung carcinomas

J. Siegfried, J. Testa, J. Resau, 1990, Genes, chromosomes & cancer.

Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era.

B. Halmos, V. Miller, J. Suh, 2016 .

An adult man presenting with hemoptysis caused by mature teratoma with rupture into the bronchus and pericardium and complicated by Haemophilus influenzae infection.

S. Keller, D. Appel, M. McLemore, 2010, The Journal of thoracic and cardiovascular surgery.

Diagnosis of palmar hyperhidrosis via questionnaire without physical examination

S. Keller, G. Swergold, R. Burk, 2009, Clinical Autonomic Research.

Adriamycin enhanced in vitro and in vivo photodynamic therapy of mesothelioma.

S. Keller, P. Brophy, 1992, The Journal of surgical research.

Intrathoracic organ injury associated with photodynamic therapy

S. Keller, M. J. Kowalyshyn, J. Pelton, 1992 .

E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC--Outcomes based on chemotherapy subsets.

H. Wakelee, D. Gandara, S. Ramalingam, 2016 .

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.

M. Tsuboi, U. Dafni, R. Stahel, 2022, The Lancet. Oncology.

24‐Month Overall Survival from KEYNOTE‐021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First‐Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

L. Sequist, H. Borghaei, S. Jalal, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current and future therapy for malignant pleural effusion.

S. Keller, 1993, Chest.

Surgical Treatment of Hyperhidrosis

S. Keller, 2010 .

Postoperative complications after combined neoadjuvant treatment of lung cancer.

W. Curran, C. Langer, S. Keller, 1993, The Annals of thoracic surgery.

Complete mediastinal lymph node dissection---does it make a difference?

S. Keller, 2002, Lung cancer.

HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus.

E. Sauter, S. Keller, M. Goldberg, 1993, Cancer letters.

Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients: Experience from a community-based academic center.

R. Perez-soler, E. Yilmaz, B. Piperdi, 2014 .

Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation

S. Horwitz, H. McDaid, S. Keller, 2007 .

Evaluation of noninvasive tests for the preoperative staging of carcinoma of the esophagus: a prospective study.

J. Roth, A. Dwyer, S. Keller, 1985, The Annals of thoracic surgery.

2 Randomized prospective comparison of adjuvant mediastinal radiation (RT) with or without concurrent chemotherapy with cisplatin and etoposide (PE) for patients with completely resected 51-3N1-2M0 non-small cell lung cancer (NSCLC): US

R. Komaki, S. Adak, R. Livingston, 1999 .

Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.

P. Camp, I. Rosas, H. Mallidi, 2017, The Annals of thoracic surgery.

Late occurrence of malignancy in a ganglioneuroma 19 years following radiation therapy to a neuroblastoma

J. Roth, P. Mckeever, A. Baker, 1984, Journal of surgical oncology.

A localized pleural based mass with intense uptake on positron emission tomography scan.

S. Keller, A. Berman, N. Shanmugam, 2007, Chest.

Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.

R. Perez-soler, C. Guha, N. Ohri, 2015, Lung cancer.

Cytogenetic abnormalities in non‐small cell lung carcinoma: Similarity of findings in conventional and feeder cell layer cultures

J. Testa, S. Keller, J. Hunt, 1993, Genes, chromosomes & cancer.

Clinical relevance of chromosome abnormalities in non-small cell lung cancer.

J. Siegfried, J. Testa, S. Litwin, 1998, Cancer genetics and cytogenetics.

Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients

A. A. Reilly, W. Han, S. Spivack, 2009, Respiratory research.

Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation.

W. Curran, S. Litwin, C. Langer, 1996, The cancer journal from Scientific American.

Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590

D. Tenen, O. Kocher, B. Halmos, 2007 .

The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.

H. McLeod, J. Kolesar, S. Marsh, 2011, Oncology reports.

Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.

M. Kris, M. Parmar, L. Stewart, 2015, The Cochrane database of systematic reviews.

Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.

R. Perez-soler, M. Lia, S. Horwitz, 2005, Cancer research.

EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer

P. Stephenson, J. Kolesar, J. Schiller, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Benign Symmetrical Lipomatosis

S. Keller, U. Kim, J. Waxman, 2014 .

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

S. Adak, R. Livingston, M. Perry, 2000, The New England journal of medicine.

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.

R. Perez-soler, S. Horwitz, H. McDaid, 2007, Cancer research.

Loss of blood group antigen a in non-small cell lung cancer

Andres J Klein-Szanto, A. Rogatko, S. Keller, 1994, Annals of Surgical Oncology.

Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.

M. Vangel, R. Komaki, R. Marks, 2004, The Journal of thoracic and cardiovascular surgery.

Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancer.

R. Gray, M. Vangel, R. Komaki, 2003, Lung cancer.

The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer.

M. Vangel, R. Marks, R. Livingston, 2002, Lung cancer.

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer

S. Adak, H. Wagner, S. Keller, 2000 .

Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy : results of sequential nonrandomized phase II studies

P. Engstrom, T. Schultheiss, L. Weiner, 1995 .

Schwannoma of the brachial plexus mimicking an apical lung tumor.

D. Kline, S. Keller, J. Horowitz, 1991, The Annals of thoracic surgery.

Significance of extramucosal residual tumor at the bronchial resection margin.

N. Martini, L. Kaiser, S. Keller, 1989, The Annals of thoracic surgery.

Blood transfusion and lung cancer recurrence

S. Groshen, N. Martini, L. Kaiser, 1988, The Annals of thoracic surgery.

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

Keunchil Park, N. Reguart, S. Jabbour, 2021, JAMA oncology.

Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.

N. Reguart, S. Jabbour, M. Reck, 2022, Journal of Clinical Oncology.

In vitro killing of human malignant mesothelioma by photodynamic therapy.

D. Taylor, J. Weese, S. Keller, 1990, The Journal of surgical research.

Intraoperative staging and surgical management of stage IIIA/N2 non-small cell lung cancer.

S. Keller, I. Brichkov, 2008, Thoracic surgery clinics.

Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer-Reply.

S. Jabbour, M. Reck, S. Keller, 2021, JAMA oncology.

18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

S. Kalnicki, B. Halmos, R. Perez-soler, 2017, International journal of radiation oncology, biology, physics.

Clinical Investigation 18 F-Fluorodeoxyglucose / Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer

S. Kalnicki, B. Halmos, R. Perez-soler, 2022 .

1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study

M. Tsuboi, H. Wakelee, J. Yang, 2020 .

Emergency and elective surgery in patients over age 70.

S. Keller, A. Aufses, L. Markovitz, 1987, The American surgeon.

MEDIASTINAL LYMPH NODE DISSECTION

S. Keller, R. Bello, 2008 .

Surgical Staging of Non-Small-Cell Lung Cancer

S. Keller, R. Bello, 2006 .

Solitary nonparasitic liver cysts.

S. Keller, A. Goldfarb, Z. Zisbrod, 1985, New York state journal of medicine.

Lung cancer transcriptomes refined with laser capture microdissection.

J. Locker, W. Han, S. Spivack, 2014, The American journal of pathology.

Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.

W. McCaskill-Stevens, S. Lippman, F. Khuri, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p53 correlates with improved survival in patients with esophageal adenocarcinoma

E. Sauter, S. Keller, S. Erner, 1995, Journal of surgical oncology.

Cultural factors associated with racial disparities in lung cancer care.

E. Halm, C. Powell, M. Wall, 2014, Annals of the American Thoracic Society.

Evaluating Beliefs Associated with Late-Stage Lung Cancer Presentation in Minorities

E. Halm, C. Powell, H. Leventhal, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mediastinal staging of lung cancer: novel concepts.

Steven M Keller, J. Annema, K. Tournoy, 2012, The Lancet. Oncology.

Blood transfusion practices after resection of intrathoracic neoplasms

S. Keller, J. Gwin, 1993, Journal of surgical oncology.

Indirect measurements of differential gene expression with cDNA microarrays.

N. Socci, M. Prystowsky, R. Perez-soler, 2004, BioTechniques.

Racial and ethnic differences in beliefs about lung cancer care.

E. Halm, C. Powell, J. Nelson, 2012, Chest.

Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis.

Hsiu-Ching Chang, A. Deitz, S. Keller, 2022, Lung cancer.

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.

H. Wakelee, R. Komaki, R. Marks, 2005, Lung cancer.

Adjuvant therapy for locally advanced non-small cell lung cancer.

S. Keller, 2003, Lung cancer.

Postoperative radiotherapy in completely resected, early-stage, non-small-cell lung cancer: reflections and future directions.

P. Granone, A. Cesario, L. Trodella, 2002, The Lancet. Oncology.

Adjuvant therapy of non small-cell lung cancer.

S. Keller, 2000, Clinical lung cancer.

Adjuvant therapy of resected non–small-cell lung cancer

S. Keller, 2000, Current opinion in oncology.

EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.

M. Tsuboi, U. Dafni, R. Stahel, 2022, Journal of Clinical Oncology.

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.

H. Fernando, Jing Yang, S. Keller, 2018 .

Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220.

V. Rusch, J. Jett, D. Gandara, 2014, The Annals of thoracic surgery.

930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

p53 and disease progression in patients with non-small cell lung cancer.

E. Sauter, S. Keller, J. Gwin, 1995, Surgical oncology.

Surgical treatment of non-small-cell lung cancer.

S. Keller, 1995, The Mount Sinai journal of medicine, New York.

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

Keunchil Park, N. Reguart, S. Jabbour, 2021 .

The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.

N. Sawabata, H. Maeda, S. Keller, 2003, Lung cancer.

Long-term survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma.

P. Catalano, A. Benson, L. Kleinberg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus

A. Benson, L. Kleinberg, P. Anné, 2007 .

Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design.

P. Catalano, A. Benson, L. Kleinberg, 2016, International journal of radiation oncology, biology, physics.

Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies.

P. Engstrom, L. Weiner, L. Coia, 1995, International journal of radiation oncology, biology, physics.

Association of Patient–Provider Communication Domains with Lung Cancer Treatment

E. Halm, C. Powell, M. Wall, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group.

S. Adak, D. Johnson, H. Wagner, 2000, The Annals of thoracic surgery.

Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation

L. Coia, E. Sauter, C. Langer, 1995, Journal of surgical oncology.

[A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer].

R. Livingston, G. Noël, J. Mazeron, 2001, Cancer Radiothérapie.

Cytogenetic abnormalities in non‐small cell lung carcinoma: Similarity of findings in conventional and feeder cell layer cultures

J. Siegfried, J. Testa, S. Keller, 1993, Genes, chromosomes & cancer.

Chromosome alterations in 21 non‐small cell lung carcinomas

J. Siegfried, J. Testa, J. Resau, 1990, Genes, chromosomes & cancer.

The effects of surgical treatment on survival and local recurrence of cutaneous malignant melanoma

S. Keller, S. Erner, Corey J. Hanger, 1992, Cancer.

Blood transfusion and lung cancer recurrence.

S. Groshen, N. Martini, L. Kaiser, 1989, Cancer.

Survival following resection of clinically occult N2 non small cell lung cancer.

S. Keller, R. Dalton, 1994, Journal of Cardiovascular Surgery.

Epidural Narcotic Analgesia After Thoracotomy

S. Keller, J. Pelton, D. J. Fish, 1993, Southern medical journal.

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.

C. Dooms, M. Tsuboi, H. Wakelee, 2023, The New England journal of medicine.

Evaluating Beliefs Associated with Late-Stage Lung Cancer Presentation in Minorities

E. Halm, C. Powell, H. Leventhal, 2013, Journal of Thoracic Oncology.

Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.

N. Reguart, S. Jabbour, M. Reck, 2020 .

Intraoperative staging and surgical management of stage IIIA/N2 non-small cell lung cancer.

S. Keller, I. Brichkov, 2008, Thoracic surgery clinics.

Pulmonary immunocytoma with massive crystal storing histiocytosis: a case report with review of literature.

M. Prasad, S. Keller, J. Sarlin, 1998, The American journal of surgical pathology.

Racial and ethnic differences in beliefs about lung cancer care.

E. Halm, C. Powell, J. Nelson, 2012, Chest.

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: Results from an ECOG prospective randomized trial of postoperative adjuvant therapy (E3590, INT0015)

J. Jett, S. Adak, R. Livingston, 2000 .